Northwest Biotherapeutics (NWBO) Current Assets (2010 - 2026)

Northwest Biotherapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 32.35% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 32.35% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 35.82% from the prior year.
• Current Assets improved to $6.2 million in Q1 2026 per NWBO's latest filing, from $5.5 million in the prior quarter.
• Across five years, Current Assets topped out at $11.8 million in Q3 2022 and bottomed at $4.1 million in Q4 2024.
• The 5-year median for Current Assets is $6.2 million (2025), against an average of $6.7 million.
• Across the five-year window, Current Assets jumped 86.46% in 2022 and slumped 56.23% in 2023, its largest moves.
• Year by year, Current Assets stood at $9.4 million in 2022, then slumped by 56.23% to $4.1 million in 2023, then fell by 1.53% to $4.1 million in 2024, then soared by 35.82% to $5.5 million in 2025, then climbed by 12.42% to $6.2 million in 2026.
• Per Business Quant, the three latest NWBO Current Assets figures stand at $6.2 million (Q1 2026), $5.5 million (Q4 2025), and $7.2 million (Q3 2025).